The offering provides temporary liquidity but does not resolve the company's fundamental challenges of FDA approval and long-term funding. The stock may face further downward pressure due to going concern issues and potential delisting. Investors should monitor the company's ability to secure additional funding and any developments with FDA approval.
Price Chart
Executive Summary
Outlook Therapeutics is conducting a $5 million public offering of 20 million shares of common stock and accompanying warrants to purchase 20 million shares at $0.25 per unit. The company faces substantial doubt about its ability to continue as a going concern, with only enough cash to fund operations into June 2026, and has received three Complete Response Letters from the FDA regarding its lead product. The offering proceeds will be used for working capital and general corporate purposes.
Key Facts
- Offering 20 million shares of common stock and 20 million warrants at $0.25 per unit for gross proceeds of $5 million
- Net proceeds estimated at $4.0 million after fees and expenses
- Company has substantial doubt about its ability to continue as a going concern
- Cash and equivalents of $8.7 million as of December 31, 2025, projected to fund operations only into June 2026
- Received third Complete Response Letter from FDA for ONS-5010/LYTENAVA with no clear path to approval
- Common stock at risk of delisting from Nasdaq due to bid price below $1.00 for 30 consecutive days
- Significant dilution for new investors with $0.49 per share dilution
Financial Impact
Approximately $4.0 million in net proceeds from the offering
Risk Factors
- Substantial doubt about going concern status
- Risk of Nasdaq delisting due to low stock price
- FDA has issued three Complete Response Letters with no clear path to approval
- Significant dilution from the offering and potential future financings
- Dependence on additional funding to continue operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-033981 |
| Document: 0001104659-26-033981-index-headers.html | 0001104659-26-033981 |
| Document: 0001104659-26-033981-index.html | 0001104659-26-033981 |
| Document: 0001104659-26-033981.txt | 0001104659-26-033981 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5778 (−23.61%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Jul 24, 2026 9w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5778 (−45.75%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5778 (−56.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access